3 Sterile Injectables, Finished Dosages and Integrated Generics Stocks With a Strong Future Roadmap: Gland Pharma, Granules India and Aurobindo Pharma
- October 22, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Gland Pharma, Granules India and Aurobindo Pharma: ROE of 9.2% to 11.7% and FY22 to FY26 revenue CAGR of 9.2% to 9.9%. Prices as of 21 Oct 2026.
Quick Answer
The three generic drug manufacturing stocks to watch are Gland Pharma, Granules India and Aurobindo Pharma. Their return on equity ranges from 9.2% to 11.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 9.9%. Granules India has the highest return on equity at 11.7%, while Gland Pharma has the fastest revenue growth at 9.9% a year. Prices are based on the 21 October 2026 close, and this article is educational, not investment advice.
Generic drug manufacturing stocks give investors exposure to companies that supply affordable medicines to regulated markets. Gland Pharma, Granules India and Aurobindo Pharma cover sterile injectables, finished dosages and a large integrated generics portfolio.
This list covers three generic drug manufacturing stocks with complete current figures: Gland Pharma, Granules India and Aurobindo Pharma. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Generic Drug Manufacturing Stocks?
Generic drug manufacturing stocks are listed companies that make off-patent medicines, active ingredients and injectables for hospitals, pharmacies and drug marketers. Their earnings depend on product approvals, plant capacity and pricing in regulated markets.
Generic Drug Manufacturing Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Gland Pharma | 2,935 | 49,953 | 44.2 | 36.0 | 9.9 | 0.03 |
| Granules India | 807.65 | 22,002 | 33.2 | 36.0 | 11.7 | 0.30 |
| Aurobindo Pharma | 1,578.8 | 92,924 | 25.0 | 36.0 | 9.2 | 0.21 |
On valuation, Granules India and Aurobindo Pharma trade at a P/E below the industry P/E, while Gland Pharma trades above it, which reflects the growth the market already expects. Readers comparing generic drug manufacturing stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Generic Drug Manufacturing Stocks Have a Strong Roadmap in India?
Generic drug manufacturing stocks have a strong roadmap in India because global healthcare systems keep seeking quality medicines at lower cost, and Indian plants are well placed to supply them.
- Patent expiries. More branded medicines lose protection, which opens room for generics.
- Injectables demand. Hospitals need steady supplies of sterile products.
- Integration. Making ingredients and finished products in-house supports supply and margins.
Why Gland Pharma Features Among These Generic Drug Manufacturing Stocks
Among the generic drug manufacturing stocks on this list, Gland Pharma is a Hyderabad-based maker of sterile injectable medicines and a leading contract manufacturer for global drug companies, with plants in India and Europe.
In the June 2026 quarter, revenue grew 19.1% year on year to Rs 1,862 crore, while net profit rose 47.1% to Rs 317 crore. Revenue rose from Rs 4,625 crore in FY22 to Rs 6,747 crore in FY26, a compound annual growth rate of 9.9%.
Net profit grew from Rs 781 crore in FY23 to Rs 1,027 crore in FY26, which works out to a compound annual growth rate of 9.6%. The company has a return on equity of 9.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 49,953 crore. The stock trades at a P/E of 44.2, above the industry P/E of 36.0.
Roadmap: Injectables are a segment where few suppliers have the technical and regulatory capability, and the company serves customers across more than 60 countries. Its partnerships with large marketers and its expanded European base support growth.
What to watch: Check new product launches and utilisation of its manufacturing capacity.
Why Granules India Features Among These Generic Drug Manufacturing Stocks
Among the injectable generics shares on this list, Granules India is a Hyderabad-based pharmaceutical manufacturer that makes active ingredients, intermediates and finished dosage forms, with a strong position in paracetamol, metformin and ibuprofen.
The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0.
Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore.
Roadmap: The company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.
What to watch: Monitor new product approvals and the share of finished dosages in total sales.
Why Aurobindo Pharma Features Among These Generic Drug Manufacturing Stocks
Among the three companies on this list, Aurobindo Pharma is a Hyderabad-based pharmaceutical company that makes generic formulations, active ingredients and injectables, with the United States and Europe as its largest markets.
Revenue rose from Rs 23,776 crore in FY22 to Rs 34,145 crore in FY26, a compound annual growth rate of 9.5%. Net profit grew from Rs 2,647 crore in FY22 to Rs 3,503 crore in FY26, which works out to a compound annual growth rate of 7.3%.
In the June 2026 quarter, revenue grew 18.1% year on year to Rs 9,415 crore, while net profit rose 25.2% to Rs 1,032 crore. The company has a return on equity of 9.2%, a debt to equity ratio of 0.21 and a market capitalisation of Rs 92,924 crore. The stock trades at a P/E of 25.0, below the industry P/E of 36.0.
Roadmap: The company is widening its range into injectables, biosimilars and complex generics while keeping a large base in oral solid dosages. Its integrated manufacturing from ingredients to finished products supports supply to regulated markets.
What to watch: Monitor new product launches and progress on its biosimilars and injectables pipeline.
Gland Pharma vs Granules India vs Aurobindo Pharma on Key Financials
The table below sets the three generic drug manufacturing stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Gland Pharma | 4,625 | 6,747 | 9.9% | 1,027 | 15.2% |
| Granules India | 3,783 | 5,386 | 9.2% | 595 | 11.0% |
| Aurobindo Pharma | 23,776 | 34,145 | 9.5% | 3,503 | 10.3% |
Granules India posts the highest return on equity in this group at 11.7%. Aurobindo Pharma has the largest FY26 revenue at Rs 34,145 crore, and Gland Pharma shows the fastest revenue growth with a 9.9% compound annual rate. A useful habit with generic drug manufacturing stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Gland Pharma | 1,563 | 1,862 | 19.1% |
| Granules India | 1,226 | 1,479 | 20.6% |
| Aurobindo Pharma | 7,973 | 9,415 | 18.1% |
Key Risks to Check Before Investing in Generic Drug Manufacturing Stocks
Every theme carries risks that deserve a check before any decision. For these generic drug manufacturing stocks, the main points are: Long-term injectable generics shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Pricing pressure. Competition can lower the prices of widely available generics.
- Regulatory inspections. Plants must keep meeting the standards of global regulators.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter generic drug manufacturing stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Generic Drug Manufacturing Stocks
Generic drug manufacturing stocks reward investors who follow approvals, plant utilisation and product mix together. Gland Pharma, Granules India and Aurobindo Pharma each bring scale and manufacturing depth. Based on the 21 October 2026 close, Gland Pharma trades at Rs 2,935, Granules India at Rs 807.65 and Aurobindo Pharma at Rs 1,578.8. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these generic drug manufacturing stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track generic drug manufacturing stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are generic drug manufacturing stocks?
Ans. Generic drug manufacturing stocks are listed companies that make off-patent medicines, active ingredients and injectables for hospitals, pharmacies and drug marketers. Their earnings depend on product approvals, plant capacity and pricing in regulated markets. This list looks at three of them, Gland Pharma, Granules India and Aurobindo Pharma, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.
Which generic drug manufacturing stocks are covered in this list?
Ans. This list covers Gland Pharma, Granules India and Aurobindo Pharma. Based on the 21 October 2026 close, Gland Pharma traded at Rs 2,935, Granules India at Rs 807.65 and Aurobindo Pharma at Rs 1,578.8. Their return on equity ranges from 9.2% to 11.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 9.9%.
Why do generic drug manufacturing stocks have a strong future roadmap in India?
Ans. Generic drug manufacturing stocks have a strong roadmap in India because global healthcare systems keep seeking quality medicines at lower cost, and Indian plants are well placed to supply them. The main drivers are as follows. Patent expiries. More branded medicines lose protection, which opens room for generics. Injectables demand. Hospitals need steady supplies of sterile products. Integration. Making ingredients and finished products in-house supports supply and margins. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Gland Pharma performed financially?
Ans. Revenue rose from Rs 4,625 crore in FY22 to Rs 6,747 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 781 crore in FY23 to Rs 1,027 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 19.1% year on year to Rs 1,862 crore, while net profit rose 47.1% to Rs 317 crore. The company has a return on equity of 9.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 49,953 crore. The stock trades at a P/E of 44.2, above the industry P/E of 36.0. Looking ahead, injectables are a segment where few suppliers have the technical and regulatory capability, and the company serves customers across more than 60 countries. Its partnerships with large marketers and its expanded European base support growth.
How has Granules India performed financially?
Ans. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.
How has Aurobindo Pharma performed financially?
Ans. Revenue rose from Rs 23,776 crore in FY22 to Rs 34,145 crore in FY26, a compound annual growth rate of 9.5%. Net profit grew from Rs 2,647 crore in FY22 to Rs 3,503 crore in FY26, which works out to a compound annual growth rate of 7.3%. In the June 2026 quarter, revenue grew 18.1% year on year to Rs 9,415 crore, while net profit rose 25.2% to Rs 1,032 crore. The company has a return on equity of 9.2%, a debt to equity ratio of 0.21 and a market capitalisation of Rs 92,924 crore. The stock trades at a P/E of 25.0, below the industry P/E of 36.0. Looking ahead, the company is widening its range into injectables, biosimilars and complex generics while keeping a large base in oral solid dosages. Its integrated manufacturing from ingredients to finished products supports supply to regulated markets.
What risks should investors check before buying generic drug manufacturing stocks?
Ans. Investors should check a few risks before buying generic drug manufacturing stocks. Pricing pressure. Competition can lower the prices of widely available generics. Regulatory inspections. Plants must keep meeting the standards of global regulators. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of generic drug manufacturing stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
